Shares of Soligenix, Inc. (SNGX) are up 364% on Thursday following the announcement that the FDA has given clearance to its Investigational New Drug (IND) application for a Phase 2a clinical trial of Dusquetide.
Soligenix, Inc. (SNGX) Monday reported a narrower net loss for the third quarter compared to the prior year. Revenues were down from the previous year. The late-stage biopharmaceutical company reported net loss of $1.
Following profit taking in Presco and 20 stocks, negative sentiments resurfaced on the Nigerian Exchange Limited (NGX), yesterday, causing the All-Share Index (ASI) to dip by 0.2 per cent.
Despite prolonged inflation, interest rate hike, insecurity and other macroeconomic challenges, the Nigerian Exchange Limited (NGX) emerged as the second best-performing exchange in Africa in the last three months.